Phase 3 Pulmonary Disease, Chronic Obstructive Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline960 enrolled159 locationsNCT06961214
Recruiting
Phase 3
Trial to Determine Effective Aspirin Dose in COPD
Pulmonary Disease, Chronic Obstructive
Johns Hopkins University48 enrolled1 locationNCT05265299
Recruiting
Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline1,196 enrolled6 locationsNCT07177339
Recruiting
Phase 3
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive (COPD)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.594 enrolled4 locationsNCT07039669
Recruiting
Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline981 enrolled15 locationsNCT06959095